Alembic Pharmaceuticals has reported results for second quarter ended September 30, 2020.
The company has reported 29.63% rise in its net profit of Rs 348.30 crore for the quarter under review as against net profit of Rs 268.69 crore for the same quarter in the previous year. Total income of the company increased 23.58% at Rs 1402.84 crore for Q2FY21 as compared Rs 1135.18 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported 35.37% rise in its net profit after taxes, non-controlling interests and share of profit of Associates and Joint Ventures at Rs 333.37 crore for the quarter under review as against net profit of Rs 246.27 crore for the same quarter in the previous year. Total income of the company increased by 17.65% at Rs 1460.32 crore for Q2FY21 as compared Rs 1241.23 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1783.55 |
| Dr. Reddys Lab | 1277.80 |
| Cipla | 1400.70 |
| Zydus Lifesciences | 1088.90 |
| Lupin | 2268.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: